Pharma BD Deal Intelligence

AstraZeneca PLC / Bristol-Myers Squibb diabetes alliance assets

2013 · Asset Purchase · $4.3B · Complete

Announcement Sentiment

Strongly positive

AstraZeneca acquired BMS's interests in the BMS-AZ diabetes alliance for $2.7B upfront plus up to $1.4B in regulatory/launch/sales milestones plus royalty payments through 2025 plus up to $225M asset-transfer payments.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Mixed

Assessment window: 5yr post-close.

Key facts

Announced Dec 19, 2013
Closed Feb 01, 2014
Deal value $4.3B
Deal type Asset Purchase
Therapeutic area Type 2 Diabetes
Indications Type 2 Diabetes
Key assets Onglyza (saxagliptin), Farxiga (dapagliflozin), Bydureon (exenatide), Byetta, Symlin
Mechanism DPP-4 inhibitor, SGLT-2 inhibitor, GLP-1 agonist, amylin analog

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals